CancerVisit

@CancerVisit_com

🎗 One stop shop for Cancer information for patients, families, and healthcare providers. #nutrition #wellbeing #cancercare

Austin, TX CancerVisit.com Joined December 2020

4.2K Following 3.7K Followers 2K Posts

Latest posts 5

CancerVisit @CancerVisit_com May 29

@MedNewsWeek @ECTAdvisor @CParkMD @ASCO #ASCO26

Ziad Bakouny, MD, MSc @ZiadBakouny May 29

So proud of this @IMG_Oncologists group @ASCO!
Thankful for everyone’s efforts to advance the cause of IMGs in oncology #ASCO26
View quoted post on X

CancerVisit @CancerVisit_com May 29

@MedNewsWeek @ECTAdvisor @CParkMD @ASCO #ASCO26

The Lancet Verified account @TheLancet May 29

Presented at #ASCO26—OptiTROP-Lung05 phase 3 interim analysis.

The findings suggest first-line treatment with sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly prolonged PFS vs pembrolizumab alone in patients with PD-L1-positive advanced NSCLC without targetable genomic alterations.

Read more: spkl.io/601976v7P

$Figure: Progression-free survival as assessed by blinded independent central review.\n\n(A) Kaplan\u2013Meier estimates of progression-free survival as assessed by blinded independent central review. (B) Forest plot of progression-free survival in subgroups. One patient with thymoma was excluded from the pembrolizumab group in the subgroup analysis of histologic type. Subgroup analyses will not be presented for any subgroup variable in which one or more levels account for less than 10% of the total analysis population. Confidence intervals have not been adjusted for multiplicity and should not be used to infer statistical significance. Sac-TMT=sacituzumab tirumotecan. PD-L1=programmed death ligand 1. TPS=tumour proportion score. NR=not reached. NE=not estimable.$
View quoted post on X

CancerVisit @CancerVisit_com May 29

@MedNewsWeek @ECTAdvisor @CParkMD @ASCO #ASCO26

Dee Sparacio @womenofteal May 29

#ASCO26 Gyn Oral Abstracts #gyncsm CHRONO: A randomized ph II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer. ( 3 cycles of chemo then surgery vs 6 cycles chemo then surgery.) 10% each arm HIPEC. QOL no significant difference

View quoted post on X

CancerVisit @CancerVisit_com May 29

@MedNewsWeek @ECTAdvisor @CParkMD @ASCO #ASCO26

QianJanieQin @QianJanieQin May 29

#SAKK06/19: intravesical recombinant BCG (#VPM1002BC) + periop chemoIO in #MIBC showed promising activity w/ pCR 65%, pathologic resp 80%. Feasible delivery/no unexpected safety signals. Encouraging data/consideration when thinking about bladder preservation? #ASCO26 #DrCathomas

View quoted post on X

CancerVisit @CancerVisit_com May 29

@MedNewsWeek @ECTAdvisor @CParkMD @ASCO #ASCO26

Álvaro Pinto @dralvaropinto May 29

AMBASSADOR HRQoL data with adjuvant Pembro for MIBC #ASCO26

View quoted post on X